Tumor T<sub>1</sub> Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Modelopen access
- Authors
- Ravoori, Murali K.; Nishimura, Masato; Singh, Sheela P.; Lu, Chunhua; Han, Lin; Hobbs, Brian P.; Pradeep, Sunila; Choi, Hyun J.; Bankson, James A.; Sood, Anil K.; Kundra, Vikas
- Issue Date
- Jun-2015
- Publisher
- PUBLIC LIBRARY SCIENCE
- Citation
- PLOS ONE, v.10, no.6
- Journal Title
- PLOS ONE
- Volume
- 10
- Number
- 6
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73750
- DOI
- 10.1371/journal.pone.0131095
- ISSN
- 1932-6203
- Abstract
- Purpose To assess whether T-1 relaxation time of tumors may be used to assess response to bevacizumab anti-angiogenic therapy. Procedures: 12 female nude mice bearing subcutaneous SKOV3ip1-LC ovarian tumors were administered bevacizumab (6.25ug/g, n=6) or PBS (control, n=6) therapy twice a week for two weeks. T-1 maps of tumors were generated before, two days, and 2 weeks after initiating therapy. Tumor weight was assessed by MR and at necropsy. Histology for microvessel density, proliferation, and apoptosis was performed. Results Bevacizumab treatment resulted in tumor growth inhibition (p<0.04, n=6), confirming therapeutic efficacy. Tumor T-1 relaxation times increased in bevacizumab treated mice 2 days and 2 weeks after initiating therapy (p<.05, n=6). Microvessel density decreased 59% and cell proliferation (Ki67+) decreased 50% in the bevacizumab treatment group (p<.001, n=6), but not apoptosis. Conclusions Findings suggest that increased tumor T-1 relaxation time is associated with response to bevacizumab therapy in ovarian cancer model and might serve as an early indicator of response.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73750)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.